ALS drug trial halted early: what we learned about brain inflammation
NCT ID NCT04066244
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an experimental drug called BLZ945 in 28 people with ALS to see if it could reduce brain inflammation. Researchers used special PET scans to measure inflammation. The study was terminated early, so the full results are not available, but it aimed to gather safety and biological data.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BLZ945
What this could lead to
If successful, this could point toward a way to reduce brain inflammation in ALS, potentially slowing disease progression.
What could go wrong
This was a small, early-stage study that was terminated, so results are limited. It is unclear if BLZ945 is safe or effective for ALS.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Novartis Investigative Site
Turku, 20520, Finland
-
Novartis Investigative Site
Stockholm, 14186, Sweden
-
Yale University School of Medicine
New Haven, Connecticut, 06520-8048, United States